alexa The Newest Frontier in Cholesterol Management; PSCK 9
ISSN: 2329-6607

Cardiovascular Pharmacology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

The Newest Frontier in Cholesterol Management; PSCK 9

Alexander Dashwood* and Jayasinghe R

Gold Coast University Hospital, Queensland, Australia

*Corresponding Author:
Alexander Dashwood
Unit 1001 Kirra Surf Apartments
2 Creek Street, Kirra, 4225, QLD, Australia
Tel: 1300 74 4284
E-mail: [email protected]

Received date: November 24, 2014; Accepted date: December 08, 2014; Published date: December 10, 2014

Citation: Dashwood A, Jayasinghe R (2015) The Newest Frontier in Cholesterol Management; PSCK 9. Cardiol Pharmacol 4:127. doi:10.4172/2329-6607.1000127

Copyright: © 2015 Dashwood A et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Cardiovascular disease from atherosclerosis remains a major cause of death in Australia. Epidemiological studies have demonstrated that reducing low-density lipoprotein cholesterol (LDL-C) strongly correlates with improved cardiovascular risk in. Although statin based therapy remains our most effective and first line therapy, certain cohorts remain refractory to their benefits. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a monoclonal antibody, is currently under research as a novel non-statin based therapy in multiple clinical trials. PCSK9 targets low-density lipoprotein receptors for internalisation and lysomal degradation. This affects cholesterol homeostasis by reducing the cells ability to internalise circulating apoliprotein B. Early trials have shown clear benefits in LDL-C reduction without major adverse incidence in populations intolerant to statins, those with familial hypercholesterolaemia and patients requiring additional treatment to meet cholesterol targets despite statin based therapy. This article is a clinical focus reviewing the current phase I, II and III trials being conducted and the potential benefits a monoclonal antibody to PCSK9 may hold for cholesterol regulation in the future.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version